Evidence map›Paper›PMID 34290540›Full record

ArticleClinical Medicine Insights. Oncology2021

Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report.

Yao Wang, Ying Gao, Hai-Ruo Chen, Hong Liu, Xi Fu, Ran Yan, Feng-Ming You, Zhuo-Hong Li

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yao WangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0003-1020-7278
Ying GaoHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Hai-Ruo ChenHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Hong LiuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Xi FuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Ran YanHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Feng-Ming YouHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Zhuo-Hong LiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we reported the rare case of primary pleural squamous cell carcinoma (PPSCC) in a 71-year-old male patient. After chemo and targeted therapies, the patient showed continuous tumor progression and clinical deterioration. Fortunately, the patient had a high expression level of PD-L1 (80%) in the tumor tissues. Ultimately, the patient survived for additional 6 months with camrelizumab treatment. In summary, camrelizumab may be a good candidate for the treatment of PPSCC, especially in tumors with high PD-L1 expression.

Indexed as

camrelizumabcase reportPrimary pleural squamoustherapeutic

Identifiers

PMID34290540
PMCPMC8278452
OpenAlexW3179745493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.